Clinical Trials Logo

HCC clinical trials

View clinical trials related to HCC.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06463444 Recruiting - HCC Clinical Trials

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

Start date: June 1, 2024
Phase: Phase 1
Study type: Interventional

Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected. Local and systemic therapy are the main treatments for unresectable HCC. Two recent trials of HAIC combined with PD-1 monoclonal antibody and targeted therapy reported objective response rates (ORR) as high as 43.3% to 77.1%.

NCT ID: NCT06413017 Recruiting - HCC Clinical Trials

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Start date: August 31, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, open-label, single-arm clinical study of nimotuzumab in combination with immune checkpoint inhibitors in patients with advanced liver cancer who have failed first-line therapy

NCT ID: NCT06311942 Recruiting - HCC Clinical Trials

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. What can be done to improve the surgical prognosis of this group of patients needs to be continuously explored.

NCT ID: NCT06311929 Recruiting - HCC Clinical Trials

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.

NCT ID: NCT06184152 Recruiting - Clinical trials for Hepatocellular Carcinoma

CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

Start date: November 28, 2023
Phase:
Study type: Observational

The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.

NCT ID: NCT05873244 Recruiting - HCC Clinical Trials

CXD101 in Immunotherapy-related Liver Cancer

Start date: August 21, 2023
Phase: Phase 2
Study type: Interventional

For hepatocellular carcinoma (HCC), durable responses and improved survivals have been reported in clinical trials on immune checkpoint inhibitor (ICI)-based treatment. However, resistance to ICI is increasingly encountered in clinical practice in HCC patients. Various approaches are currently evaluated in clinical setting to tackle acquired resistance during treatment of ICIs in HCC. Our group has a track record of studying the role of histone deacetylases (HDACs) in mediating resistance to ICI in HCC. First, based on single-cell sequencing data of serial biopsy of tumor in our phase II clinical trial on pembrolizumab in HCC (NCT03419481), the investigators reveal an upregulation of class 1 HDAC in patients with acquired resistance to pembrolizumab, which was associated with reduced lymphoid/myeloid cellular ratio in the tumor. Further, the investigators showed that HDAC8, a class 1 HDAC, could diminish the efficacy of anti-programmed cell death (ligand)-1 (PD[L]-1) by the mechanism of T-cell exclusion from the tumor environment (SciTranl Med. 2021;13:online). Finally, the investigators combine CXD101, a potent selective class I HDAC inhibitor, with anti-PD(L)-1 in orthotopic immunocompetent HCC mouse model with resistance to anti-PD(L)-1 treatment and find that the combination regimen could reverse the resistance phenotype and significantly improve survivals of mice than either CXD101 or anti-PD(L)-1 alone.

NCT ID: NCT05788835 Recruiting - HCC Clinical Trials

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

Start date: March 7, 2023
Phase: N/A
Study type: Interventional

This is a randomized controlled trial to determine the efficacy and safety of DEB-TACE versus DEB-TACE sequential HAIC for unresectable BCLC stage C HCC

NCT ID: NCT05781568 Recruiting - NAFLD Clinical Trials

Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)

GALAD
Start date: February 24, 2023
Phase:
Study type: Observational

The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in high-risk subjects to develop this neoplasm. In particular, it aims to: - Evaluate the clinical utility of the combined use of α-FP, α-FP-L3 and DCP in predicting the onset of HEPATOCARCINOMA (HCC); - Evaluate the performance of GALAD and GALADUS scores in the early diagnosis of HCC; - Evaluate the association between the levels of the three biomarkers (individually and in combination with each other) and the stage of HCC

NCT ID: NCT05592171 Recruiting - HCC Clinical Trials

Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC

SEASON-HCC
Start date: October 17, 2022
Phase: N/A
Study type: Interventional

The goal of this Interventional Study is to compare the efficacy profile and safety of three treatments in patients with HCC nodule. Patients will be randomly divided in three arms: 1. Occlusafe assisted MWA+ DEB-TACE 2. Occlusafe assisted MWA 3. MWA+ DEB-TACE The primary objectives are evaluate the safety of the three treatments; evaluate the effectiveness of treatments one month after the procedure (defined as complete ablation of macroscopic tumor at one month of follow-up), verifying the possible superiority of arm 1 and arm 2 compared to arm 3. The secondary objective is: time to local disease recurrence.

NCT ID: NCT05581004 Recruiting - Gastric Cancer Clinical Trials

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: October 20, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.